Immunome (IMNM) vs Prestige Consumer Healthcare (PBH)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Immunome (IMNM) has outperformed Prestige Consumer Healthcare (PBH) over the past year, gaining 36.8% versus a loss of 23.2%. Over five years, IMNM leads with a +11.0% price change compared with -17.4% for PBH. Immunome is the larger company by market cap ($2.31 billion vs $2.28 billion), about 1.0 times the size, while Prestige Consumer Healthcare is growing revenue faster (-4.3% vs -23.2%).
Prestige Consumer Healthcare converts more of its revenue into profit, with a net margin of 17.5% versus -3060.0%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IMNM | PBH |
|---|---|---|
| Share price | $19.55 | $48.23 |
| Market cap | $2.31B | $2.28B |
| 1-day change | +1.24% | +0.75% |
| YTD return | -8.99% | -21.82% |
| 1-year return | +36.81% | -23.19% |
| 5-year return | +11.02% | -17.44% |
| P/E ratio (TTM) | — | 13.51 |
| Forward P/E | — | 9.49 |
| EPS (TTM) | $-2.52 | $3.57 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $6.94M | $1.09B |
| Revenue growth (YoY) | -23.23% | -4.31% |
| Net income (latest FY) | $-212.39M | $190.30M |
| Gross margin | — | 54.71% |
| Operating margin | -3228.83% | 28.42% |
| Net margin | -3059.99% | 17.48% |
| 52-week high | $30.06 | $71.07 |
| 52-week low | $13.54 | $42.62 |
| Distance from 52-week high | -34.96% | -32.14% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +80.05% | +40.58% |
| Average volume | 1.21M | 547.31K |
| Shares outstanding | 118.00M | 47.37M |
| Employees | 247 | 890 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IMNM has outperformed PBH by 60.0 percentage points over the past year.
- Prestige Consumer Healthcare is more profitable, keeping 17.5 cents of every revenue dollar as net income versus -3060.0 cents for Immunome.
- Prestige Consumer Healthcare grew revenue faster in its latest fiscal year (-4.31% vs -23.23%).
About Immunome
IMNM stock →Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial.
Health Care · Biotechnology: Pharmaceutical Preparations · 247 employees
About Prestige Consumer Healthcare
PBH stock →Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over the counter (OTC) health and personal care products in North America, Australia, and internationally. It operates in two segments, North American OTC Healthcare and International OTC Healthcare.
Health Care · Biotechnology: Pharmaceutical Preparations · 890 employees
IMNM vs PBH FAQ
Which is bigger, Immunome or Prestige Consumer Healthcare?
Immunome (IMNM) is larger, with a market capitalization of $2.31B compared with $2.28B for Prestige Consumer Healthcare (PBH).
Which stock has performed better over the past year, IMNM or PBH?
IMNM returned +36.81% over the past 12 months, compared with -23.19% for PBH (price return, excluding dividends). Past performance does not predict future results.
Are Immunome and Prestige Consumer Healthcare in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.